USEFULNESS OF SERUM (1, 3) BETA D GLUCAN IN DIAGNOSIS OF PNEUMOCYSTIS JIROVECII PNEUMONIA IN IMMUNOCOMPROMISED PATIENTS

Background and study aim: The current study aims to figure out the use of the serological 1, 3 Beta-D -Glucan (BDG) test for early detection of Pneumocystis jirovecii Pneumonia (PcP) among immuno - compromised patients with acute respiratory distress syndrome (ARDS). Patients and methods: This are a cross-sectional study. It was carried out at Ain Shams University Hospitals on immunocompromised patients presenting with pneumonia. The study included 44 clinically relevant patients, with lower respiratory tract infections, based on their clinical presentation and chest radiological findings. The group included 26 males and 18 females. Their ages ranged from 1 to 74 years. Results: Out of 44 immunocompromised Patients with ARDS caused by Invasive Fungal Infections (IFI) suspected PcP according to clinical, radiological findings and Galactomannan, those patients included patients in ICU, with haematological malignancies, on immunosuppressive drugs and HIV positive Patients. 72.7 % were positive for BDG, while 27.3 % were negative for BDG. Positive predictive value of BDG was 75 % while BDG’s negative predictive value 91.7 %. Our results figured out also that there was a statistically significant relation between results of BDG and Galactomannan with Value < 0.001, lymphocytic count with P Value 0.005 and LDH level with P Value 0.017. Sensitivity of the test was 96% while Specificity was 57.9% Conclusions: Pneumocystis jirovecii pneumonia represents a huge burden to immunocompromised patients in the intensive care unit (ICU) and those with haematological malignancies, particularly those with lymphoproliferative diseases. Increased rates of ICU admissions for respiratory failure and fatalities are linked to the disease. BDG is a non-invasive diagnostic technique that has a high negative predictive value and can rule out IFI. However, neither do its serum levels accurately reflect the severity of the illness nor are they useful for gauging treatment effectiveness.

[1]  Y. Le Govic,et al.  A Negative (1,3)-β-D-Glucan Result Alone Is Not Sufficient to Rule Out a Diagnosis of Pneumocystis Pneumonia in Patients With Hematological Malignancies , 2021, Frontiers in Microbiology.

[2]  F. Robert-Gangneux,et al.  Molecular diagnosis of Pneumocystis pneumonia in immunocompromised patients. , 2019, Current opinion in infectious diseases.

[3]  P. White,et al.  Diagnosis and management of Pneumocystis jirovecii infection , 2017, Expert review of anti-infective therapy.

[4]  L. Weng,et al.  Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study , 2016, BMC Infectious Diseases.

[5]  M. Yigla,et al.  Does molecular analysis increase the efficacy of bronchoalveolar lavage in the diagnosis and management of respiratory infections in hemato-oncological patients? , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[6]  Allen R. Chen,et al.  The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR® analysis , 2015, Bone Marrow Transplantation.

[7]  F. Antunes,et al.  (1–3)-Beta-D-glucan in association with lactate dehydrogenase as biomarkers of Pneumocystis pneumonia (PcP) in HIV-infected patients , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[8]  Huiping Li,et al.  Evaluation of PCR in Bronchoalveolar Lavage Fluid for Diagnosis of Pneumocystis jirovecii Pneumonia: A Bivariate Meta-Analysis and Systematic Review , 2013, PloS one.

[9]  J. Held,et al.  β-d-Glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  J. Verhaegen,et al.  Serum (1-3)-β-d-Glucan as a Tool for Diagnosis of Pneumocystis jirovecii Pneumonia in Patients with Human Immunodeficiency Virus Infection or Hematological Malignancy , 2009, Journal of Clinical Microbiology.

[11]  A. Kedzierska,et al.  Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1→3)-β-D-glucan antigens , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[12]  K. Saito,et al.  Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases. , 2004, Rheumatology.

[13]  M. Robin,et al.  Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  T. Pumarola,et al.  Prognostic factors of non-HIV immunocompromised patients with pulmonary infiltrates. , 2002, Chest.

[15]  L. Mele,et al.  Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres , 2002, British journal of haematology.

[16]  T. Navin,et al.  Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. , 1998, The Journal of infectious diseases.

[17]  H. Einsele,et al.  ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. , 2016, The Journal of antimicrobial chemotherapy.

[18]  M. Falagas,et al.  Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  仲村 秀太.  Clinical utility of serum β-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia , 2011 .

[20]  A. Morris,et al.  Epidemiology and clinical significance of pneumocystis colonization. , 2008, The Journal of infectious diseases.

[21]  M. Finkelman,et al.  b - d -Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cutoff Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome , 2004 .